Combination drug treatment for acute ischemic stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether adding a drug called human urinary kallidinogenase to standard clot-busting therapy with reteplase improves outcomes for people having a first or recurrent ischemic stroke. It is designed for patients who can start treatment within 4.5 hours of symptoms and have moderate stroke severity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your diagnosis matches the Chinese guidelines for acute ischemic stroke.
- You are 18 years or older.
- You can start treatment within 4.5 hours from when you were last seen normal.
- This is your first stroke, or a past stroke left you with little or no disability (modified Rankin score 0–1) before this one.
- Your stroke severity at the start is moderate, with a score between 6 and 16 on the NIH stroke scale.
- You and your doctor agree to receive reteplase as the clot-busting drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This trial tests a drug called urinary kallidinogenase to see if it helps people who have had a stroke caused by a large artery in the brain becoming narrowed or blocked. It is for those who can be treated within 48 hours of symptoms starting.
This trial tests a drug called Human Urinary Kallidinogenase to see if it can help people recover better after a recent stroke caused by a blockage in the front part of the brain. It is for patients who have mild to moderate symptoms and can start treatment within 2 days of the stroke.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This trial tests if a medication called Urinary Kallidinogenase can help people who have had a stroke and also have type 2 diabetes. It may improve recovery by increasing blood flow to the brain.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.